Taysha Announced New Clinical Data from the REVEAL Trials Evaluating TSHA-102

Taysha Gene Therapies is conducting, in parallel, two clinical trials to test their gene therapy, TSHA-102, in Rett syndrome. One trial, taking place in Canada and the US is for ages 12 years and older and a pediatric trial in the US and UK for ages 5 to 8 years old with a later expansion to include 3 to 5 years old. The trials are testing a low and high dose.

Today, Taysha announced new interim clinical data on the following patients all given the low dose:

Longer-term data from the first adult patient (20 years old; large MECP2 deletion; associated with severe phenotype) and second adult patient (21 years old; missense MECP2 mutation; associated with milder phenotype) with late motor deterioration, stage four Rett syndrome.

Initial results from the first pediatric patient (6 years old; MECP2 deletion; associated with moderate phenotype) and second pediatric patient (7 years old; missense MECP2 mutation; associated with milder phenotype) with pseudo stationary symptoms, stage three Rett syndrome.

NOTE: What is being reported are interim data, not final data. Making conclusions about interim data may not accurately predict the full risk/benefit profile of TSHA-102.

Please see the company's press release and Rett community letter for further information.